Article Per Year (5 Year)
p-Index From 2020 - 2025
7.721
P-Index
This Author published in this journals
All Journal Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan Jurnal Ilmu Kedokteran (Journal of Medical Science) Jurnal Kesehatan Andalas Global Medical and Health Communication Biomedical Journal of Indonesia Jurnal Profesi Medika: Jurnal Kedokteran dan Kesehatan Jurnal Penelitian Pendidikan IPA (JPPIPA) Window of Health : Jurnal Kesehatan Majalah Kedokteran Andalas Majalah Patologi Indonesia Bioscientia Medicina : Journal of Biomedicine and Translational Research Majalah Kedokteran Neurosains Human Care Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Jurnal Ners Science Midwifery Nusantara Hasana Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Cermin Dunia Kedokteran Jurnal Ilmu Kesehatan Indonesia (JIKSI) Journal of Pharmaceutical and Sciences. Neurona Jurnal Ilmiah Manuntung: Sains Farmasi dan Kesehatan
Yuliarni Syafrita
Department Of Neurology, Faculty Of Medicine, Universitas Andalas, Padang, Indonesia.
Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Dentistry Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Veterinary

Published : 74 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search
Journal : Bioscientia Medicina : Journal of Biomedicine and Translational Research

 1   2 
Relationship of Serum Tau Levels with Cognitive Functions and Factors Affecting The Cognitive Function Decrease in Parkinson's Disease Patients Meldayeni Busra; Yuliarni Syafrita; Hendra Permana
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 6 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i6.317

Abstract

Introduction: Cognitive impairment is a non-motor symptom of Parkinson's disease (PD) which occurs as the disease progresses and affects quality of life. Many efforts have been developed in early detection of cognitive disorders, one of which is the examination of tau protein biomarkers, where the tau protein that undergoes pathological changes to form neurofibrillary tangles (NFTs) is found in Alzheimer's disease and PD and plays a role in cognitive impairment. However, the role of tau in PD is still controversial. This study aims to assess the relationship between serum tau levels and cognitive function and the factors that affect cognitive function in PD patients. Methods: This cross-sectional design was conducted at the RSUP DR. M Djamil Padang. During the period March to August 2020, 62 research subjects were obtained. Cognitive function examination was carried out by using the MoCA-Ina test and examination of serum tau levels using the Elisa method. The relationship between categorical variables was tested by Chi square and differences in serum tau levels in the group with and without cognitive impairment were tested with the Mann Whitney test, considered statistically significant if the p value <0.05. Results: With Moca Ina examination, it was found that 67.7% of patients had impaired cognitive function. The mean serum tau level was 198.004 ± 162.69 ng / L.There was a significant relationship between education level and degree of disease with cognitive function (p <0.05) and there was no difference in mean serum tau levels between groups with and without cognitive impairment. Conclusion: There is a significant relationship between education level and degree of disease with cognitive function and there is no difference in mean serum tau protein levels between the cognitive impaired group and the cognitive normal group.
Analysis of Neuron Specific Enolase Serum Levels in Traumatic Brain Injury Yuliarni Syafrita; Nora Fitri
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 4 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i4.413

Abstract

Background : Traumatic brain injury is still the main cause of death and disability in productive age. Assessment the level of consciousness and imaging examinations after a brain injury can not always describe the severity of damage in the brain, this is because the pathological process is still ongoing due to secondary brain injury. Therefore, it is necessary to examine biomarkers that can describe the severity of the pathological process that occurs. The purpose of this study was to assess serum neuron-specific enolase (NSE) levels and their relationship to the severity and outcome of a traumatic brain injury. Methods : A cross sectional design was conducted in the emergency department of DR M Djamil Hospital, Padang. There were 72 patients who met the inclusion criteria. A Glasgow Coma Scale examination was performed to assess the severity of brain injury and examination of NSE serum levels at 48 hours post- injury using ELISA technique and assess the Glasgow outcome scale (GOS) at 6 weeks post-injury. Data analysis using SPSS 22 program, the results are significance if the p value <0.05 Results : The average NSE level was higher in severe brain injuries than moderate and mild brain injuries and this difference was statistically significant (p<0.05). The NSE serum levels were higher in poor outcomes than in good outcomes and this difference was statistically significant (p<0.05). Conclusion : High NSE serum levels in the acute phase were associated with the severity of the brain injury and poor outcome 6 weeks after the brain injury.
Serum Vitamin D Levels Related to Cognitive Function in Chronic Kidney Disease Patients Elsi Rahmadhani Hardi; Yuliarni Syafrita; Syarif Indra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 13 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i13.640

Abstract

Background: Vitamin D acts as a neuroprotector and modulator in the central nervous system. Hypovitaminosis is a risk factor for cognitive dysfunction. Hypovitaminosis D and impaired cognitive function are common in patients with chronic kidney disease. Impaired cognitive function is comorbid that can increase the morbidity and mortality of patients with chronic kidney disease. This study aims to assess the relationship between serum vitamin D levels and cognitive function in patients with chronic kidney disease. Methods: This research is an observational study with a cross-sectional approach. A total of 60 research subjects participated in this study. Sociodemographic data, cognitive function, and vitamin D levels were analyzed in this study. Data analysis was performed with SPSS 25 to perform univariate and bivariate tests. Results: The impaired cognitive function was found in 56.7% of CKD patients. The median serum vitamin D level of patients with chronic kidney disease with impaired cognitive function was 30.80 ng/mL and without impaired cognitive function 42.98 ng/mL. There was a significant relationship between serum vitamin D levels and impaired cognitive function (OR=4.125, p=0.035). The cut-off point of serum vitamin D levels associated with impaired cognitive function in CKD patients was 34.8 ng/mL (sensitivity 64.7% and specificity 69.2%). Conclusion:There is a significant relationship between serum vitamin D levels and the incidence of cognitive dysfunction in patients with chronic kidney disease. The cut-off point for serum vitamin D levels associated with impaired cognitive function in chronic kidney disease is 34.8 ng/mL.
Relationship of Parathyroid Hormone Levels with Uremic Neuropathy in Chronic Kidney Disease Patients Rizki Muhammad Rananda; Yuliarni Syafrita; Restu Susanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 16 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i16.697

Abstract

Background: Parathyroid hormone is known as one of the main uremic toxicants, which, if the amount increases in plasma, will affect motor conduction in patients with chronic kidney disease. This study aims to determine the relationship between Parathyroid hormone levels with uremic neuropathy in patients with chronic kidney disease. Methods: This study was an analytic observational study with a cross-sectional approach, where as many as 42 subjects participated in this study. Data analysis was performed using SPSS using univariate and bivariate, with p<0.05. Results: There was a difference in the average thyroid hormone levels in neuropathy and without neuropathy, but statistically, it was not different p>0.05. Conclusion: There is no relationship between parathyroid hormone and uremic neuropathy in patients with chronic kidney disease.
The Relationship between Serum Cystatin-C Levels and Impaired Cognitive Function in Patients with Chronic Kidney Disease Anggi Anugerah Basir; Yuliarni Syafrita; Syarif Indra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.777

Abstract

Background: Cystatin-C acts as a neuroprotector in the central nervous system at normal levels, but high serum cystatin-C levels are associated with impaired cognitive function. Serum cystatin-C levels increase in impaired renal function, and cognitive impairment are comorbidities that can increase the morbidity and mortality of chronic kidney disease patients. This study aimed to assess the relationship between serum cystatin-C levels and cognitive function in chronic kidney disease patients. Methods: This study used a cross-sectional design with 73 samples of non-hemodialysis chronic kidney disease patients. Cognitive function was assessed using the MoCa-Ina. Serum cystatin-C levels of all samples were measured by the ELISA method. Data analysis was carried out using SPSS. Results: Impaired cognitive function in CKD patients was found to be 76.7%. The median serum cystatin-C level of CKD patients with impaired cognitive function (n=56) was 1.015 mg/dL, and without cognitive impairment (n=17) was 0.929 mg/dL. There was no significant relationship between serum cystatin-C levels (cut-off point 0.98 mg/dL) and impaired cognitive function (OR : 2.05, 95% CI : 0.680-6.175, p= 0.198). Conclusion: There is no relationship between serum cystatin-C levels and cognitive function impairment in non-hemodialysis chronic kidney disease patients.
The Relationship between Dickkopf-Related Protein-1 (DKK-1) Plasma Levels and Impaired Cognitive Function in HIV Patients Yulia Trisna; Yuliarni Syafrita; Restu Susanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.780

Abstract

Background: Dickkopf-related protein – 1 (DKK-1) is an antagonist protein to the Wingless (Wnt)-β catenin signal. Dysregulation of Wnt-β catenin signaling by DKK-1 causes disruption of neuronal synapses, which can result in impaired cognitive function. Impaired cognitive function in people with HIV or HIV-associated neurocognitive disorder (HAND) is a spectrum of cognitive disorders related to HIV neuroinvasion and neuroinflammation, which significantly results in impaired cognitive function and daily activity. This study aimed to assess the relationship between plasma DKK-1 levels and impaired cognitive function in HIV patients. Methods: This study used a cross-sectional design, consisting of 84 HIV sufferers who went to the voluntary counseling and testing (VCT) polyclinic at Dr. M. Djamil General Hospital, Padang, Indonesia, in the period December 2022 - March 2023, who met the inclusion and exclusion criteria. Cognitive function was assessed using the Montreal Cognitive Assessment Indonesian version (MoCa-Ina), and daily activity function using the instrumental activity of daily living (IADL) examination. Plasma DKK-1 levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. Results: The mean plasma DKK-1 level of HIV sufferers was 358.4 (+ 157.6) pg/mL. ANI type disorder was found in 78.6%, MND in 21.4%, and no HAD type. There was a significant relationship between plasma DKK-1 levels and impaired cognitive function in HIV patients (OR = 2.82, CI95% = 1.128-7.043, p = 0.025), but there was no significant difference in plasma DKK-1 levels between types of cognitive impairment ANI and MND (p = 0.858). Conclusion: Plasma DKK-1 levels are significantly associated with impaired cognitive function in HIV patients.
Characteristics of Adult Sepsis Patients Admitted to Department of Internal Medicine, Dr. M. Djamil General Hospital, Padang, Indonesia Elvia Fataya; Fadrian; Mustafa Noer; Dwitya Elvira; Yuliarni Syafrita; Netti Suharti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i3.791

Abstract

Background: Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. Septic shock is the most dangerous complication of sepsis, characterized by abnormalities in the circulatory and metabolic systems. This study aimed to determine the characteristics of adult sepsis patients admitted to the department of internal medicine of Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: This research was a descriptive study and used secondary data from medical records. Samples in this study were medical record data from the medical record installation of Dr. M. Djamil General Hospital, Padang, Indonesia. The inclusion criteria were adult patients aged more than 18 years old, diagnosed with sepsis, and hospitalized in the department of internal medicine for the period of January 2020 to December 2021. Results: Most of the sepsis patients were mostly aged more than 60 years old (51.7%), female (57.2%), and had normal BMI scores (59.3%). The infections mainly originated from the lungs (80%), the most common comorbid disease was chronic kidney disease (26.4%), the most frequent causing microorganism was Escherichia coli (15.9%), the frequent degree of severity was a septic shock (60%), and cefepime was used as the initial empirical antibiotic (44.8%). Conclusion: Most sepsis patients were adults aged more than 60 years old and females, with the focus on infection originating from the lungs, degree of severity in the form of septic shock, and the most used initial empirical antibiotic, namely cefepime.
The Relationship between Plasma Glutamate Levels and Sleep Quality in HIV Patients Dhiang Mulia Syofiadi; Yuliarni Syafrita; Lydia Susanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 11 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i11.884

Abstract

Background: Disturbance sleep quality is often found in sufferers of human immunodeficiency virus (HIV). Disturbed sleep quality can affect immunity, which ultimately can increase patient morbidity and mortality. Impaired sleep quality in HIV sufferers is related to neurotoxicity due to the HIV virus, which damages sleep architecture. HIV infection can cause an increase in brain extracellular glutamate. Elevated glutamate plays a role in neuronal and glial damage and death. This study aimed to assess the relationship between plasma glutamate levels and sleep quality in HIV sufferers. Methods: The research uses a cross-sectional design. The samples were HIV sufferers in a polyclinic voluntary counseling test (VCT) internal medicine of Dr. M. Djamil General Hospital Padang, who met the inclusion and exclusion criteria. Samples are selected by consecutive methods. Sleep quality was assessed using a questionnaire called the Pittsburgh sleep quality index (PSQI). Plasma glutamate levels were measured using the ELISA method. Statistical analysis using SPSS with a p-value <0.05 was considered statistically significant. Results: The research sample consisted of 82 people. The median plasma glutamate level was 16.39 µg/mL. Impaired sleep quality was found in 45 (54.9%) HIV sufferers. There was no significant relationship between plasma glutamate levels (p= 0.506), age (p=0.795), gender (p=0.547), education (p=0.358), occupation (p=0.255), disease duration (p=0.348), stage (p=0.309) and type of ARV therapy (p=0.791) with sleep quality in HIV sufferers. From this research, a significant relationship was found between sleep quality, body mass index (BMI) (p= 0.015), and marital status (p= 0.039). Conclusion: There is no relationship between plasma glutamate levels and sleep quality in HIV sufferers. There are other factors that influence sleep quality, namely BMI and marital status.
Chemotherapy-Induced Cognitive Impairment and Neuroaxonal Damage: Investigating the Role of Serum Neurofilament Light Chain Husni Minanda Fikri; Syafrita, Yuliarni; Lydia Susanti; Syarif Indra; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i6.1319

Abstract

Background: Chemotherapy-induced cognitive impairment (CICI), colloquially termed "chemobrain," represents a significant challenge for cancer survivors, potentially affecting up to 85% of patients undergoing treatment. Diagnosis often relies on neuropsychological testing and imaging, which may lack sensitivity for early detection or reflect chronic changes. Neurofilament light chain (NfL), a neuronal structural protein released into biofluids upon neuroaxonal damage, emerges as a promising biomarker. This study investigated the relationship between serum NfL levels and the degree of cognitive impairment in patients receiving chemotherapy. Methods: An observational, cross-sectional study was conducted involving 50 cancer patients undergoing chemotherapy at Dr. M. Djamil General Hospital Padang between October and December 2024. Cognitive function was assessed using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina), and depression was screened using the Patient Health Questionnaire-9 (PHQ-9). Serum NfL levels were quantified using an Enzyme-Linked Immunosorbent Assay (ELISA) method. The Kruskal-Wallis test was employed to analyze the relationship between serum NfL levels and cognitive function status (normal, mild impairment, moderate-severe impairment). Results: Cognitive impairment (MoCA-Ina assessed) was identified in 41 (82%) of the 50 participants, with 30 (60%) exhibiting mild and 11 (22%) exhibiting moderate to severe impairment. The median serum NfL level across all subjects was 23.44 pg/ml (range: 13.81-68.71 pg/ml). A statistically significant relationship was observed between serum NfL levels and the presence and severity of cognitive impairment (p = 0.02). Median NfL levels progressively increased from the cognitively normal group (18.49 pg/ml) to the mild impairment group (23.5 pg/ml) and the moderate-severe impairment group (24.5 pg/ml). Post-hoc analysis revealed significant differences in NfL levels between the normal group and both the mild (p=0.03) and moderate-severe (p=0.01) impairment groups. Conclusion: This study demonstrated a significant positive association between serum NfL levels and the presence and severity of cognitive impairment in cancer patients undergoing chemotherapy. These findings support the potential utility of serum NfL as an accessible biomarker for detecting chemotherapy-associated neuroaxonal damage and concomitant cognitive decline.
Study Analysis of Serum Phosphorylated Tau (P-Tau) Levels with Severity and Outcome in Traumatic Brain Injury Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia Istiqomah; Syafrita, Yuliarni; Fanny Adhy Putri; Syarif Indra; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i9.1060

Abstract

Background: Traumatic brain injury (TBI) is a global health problem that can cause death and disability in people of productive age. The diagnosis and assessment of TBI severity currently still rely on clinical examination and neuroimaging. However, limited access and cost of neuroimaging are obstacles in many health facilities. Therefore, blood-based biomarkers are needed that can help the diagnosis and prognosis of TBI. Phosphorylated Tau (p-tau) is a potential biomarker that can be measured in serum. This study aims to assess the relationship between serum p-tau levels and severity and outcome in TBI patients. Methods: This research is a comparative study with a cross-sectional design involving 70 TBI patients who came to the emergency room (ER) of Dr. M. Djamil General Hospital Padang. TBI severity was assessed using the Glasgow coma scale (GCS) and grouped into mild (GCS 13-15) and moderate to severe (GCS 3-12). Outcomes were assessed using the Glasgow outcome scale (GOS) and grouped into good (GOS 4-5) and poor (GOS 1-3). Serum p-tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The median serum p-tau level in the mild TBI group was 165.84 ng/L (IQR 126.18-463.85), while in the moderate to severe TBI group, it was 177.68 ng/L (IQR 87.62-591 .93). There was a significant difference between serum p-tau levels in the mild and moderate to severe TBI groups (p=0.029). The median serum p-tau level in the good outcome group was 167.21 ng/L (IQR 87.62-463.85), while in the poor outcome group it was 187.04 ng/L (IQR 137.75-591.93). There was a significant difference between serum p-tau levels in the good and bad outcome groups (p=0.014). Conclusion: Serum p-tau levels have a significant relationship with severity and outcome in TBI patients. Elevated serum p-tau levels are associated with increased severity of TBI and poor outcomes. Further research is needed to confirm these findings and explore the potential of p-tau as a biomarker in TBI management.
Co-Authors Adang Bachtiar Afriyeni Sri Rahmi Ahmad, Baihaqi Alya Ramadhini Andi Fadilah Yusran Andy, Marfri Anggi Anugerah Basir ATTIYA ISTARINI Basjiruddin Ahmad Cintya Agreayu Dinata Darwin Amir Darwin Amir Darwin Amir, Darwin Dedi Sutia Dhiang Mulia Syofiadi Djong Hon Tjong Dwi Sri Rejeki Dwitya Elvira, Dwitya Elsi Rahmadhani Hardi Elvia Fataya Ennesta Asri Erdanela Setiawati Eryanti, Lusi Eva Chundrayetti Eva Decroli Fadel Muhammad Fadrian, Fadrian Fanny Adhy Putri Fitra Ermila Basri Gunawan Septa Dinata Haiga, Yuri Harun Harnavi Hauda El Rasyid Hendra Permana Husni Minanda Fikri Indra, Syarif Iqbal Al Rasyid Istiqomah Jabbar, Ridho Ahmad Karina Prasasti Helhid Kurniawan, Yoga Setia Lydia Susanti Lydia Susanti Lydia Susanti Lydia Susanti Lydia Susanti, Lydia M Hasan Machfoed Marfri Andy Marliana, Lesti Meldayeni Busra Mubarak, M. Dzaky Muhammad Farhan Khadaffi Mustafa Noer Nailatul Fadhilah Nela Novita Sari Netti Suharti Nora Fitri Nora Fitri Novi Yudia Nur Indrawati Lipoeto Nur Indrawaty Lipoeto Nurhayati Nurhayati Nurvalinda, Nurvalinda Pitra, Dian Ayu Hamama Putri, Fanny Adhy Rahmi Ulfa Rasyid, Hauda El Ratna D Siregar Rauza Sukma Rita Reno Bestari Reno Bestari Restu Susanti Rika Susanti Rika Susanti Rini Gusya Liza, Rini Gusya Rizanda Machmud Rizki Muhammad Rananda RR. Ella Evrita Hestiandari Russilawati, Russilawati Salmiah Agus Sukri Rahman Susila Sastri Susila Sastri Sutia, Dedi Syahrul, Muhammad Zulfadli Syarif Indra Syarif Indra Trya Mia Intani Widia Rahmawati Yantri Maputra Yanwirasti Yanwirasti Yaumi Faiza Yoga Setia Kurniawan Yulia Trisna